Human papillomavirus and cervical cancer

[1]  S. Franceschi,et al.  Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population‐based studies , 2012, International journal of cancer.

[2]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[3]  M. Einstein,et al.  Cervical Intraepithelial Neoplasia Is Associated With Genital Tract Mucosal Inflammation , 2012, Sexually transmitted diseases.

[4]  S. Garland,et al.  Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. , 2012, The Lancet Oncology.

[5]  Y. Modis,et al.  Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity , 2012, Virology Journal.

[6]  M. Einstein,et al.  Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years , 2011, Human vaccines.

[7]  R. Roden,et al.  A multimeric L2 vaccine for prevention of animal papillomavirus infections. , 2011, Virology.

[8]  Jane J. Kim.  The role of cost-effectiveness in U.S. vaccination policy. , 2011, The New England journal of medicine.

[9]  H. Jessen,et al.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.

[10]  F. Wiklund,et al.  Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[11]  S. Garland,et al.  Adolescent and young adult HPV vaccination in Australia: achievements and challenges. , 2011, Preventive medicine.

[12]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[13]  J. Ordi,et al.  Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. , 2011, Gynecologic oncology.

[14]  S. Piersma,et al.  Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients , 2011, Cancer Microenvironment.

[15]  S. Franceschi,et al.  Human papillomavirus infection in a population‐based sample of women in Algiers, Algeria , 2011, International journal of cancer.

[16]  J. Peto,et al.  A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. , 2011, European journal of cancer.

[17]  S. Franceschi,et al.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.

[18]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[19]  P. Naud,et al.  Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. , 2010, Vaccine.

[20]  E. de Villiers,et al.  Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. , 2010, Virology.

[21]  M. Stanley.  Pathology and epidemiology of HPV infection in females. , 2010, Gynecologic oncology.

[22]  H. Pitot,et al.  A role for HPV16 E5 in cervical carcinogenesis. , 2010, Cancer research.

[23]  A. Chaturvedi.  Beyond cervical cancer: burden of other HPV-related cancers among men and women. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[24]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[25]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[26]  M. Plummer,et al.  Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology , 2010, International journal of cancer.

[27]  M. Tommasino,et al.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses , 2010, Virus Genes.

[28]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[29]  R. Roden,et al.  Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches , 2009, Journal of Virology.

[30]  I. Frazer,et al.  Development of therapeutic HPV vaccines. , 2009, The Lancet. Oncology.

[31]  M. Boily,et al.  Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries , 2009, Public Health Genomics.

[32]  J. Felix,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[33]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[34]  S. Franceschi,et al.  HPV infection in women with and without cervical cancer in Conakry, Guinea , 2009, British Journal of Cancer.

[35]  D. Lowy,et al.  Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines , 2009, Journal of the National Cancer Institute.

[36]  P. Coursaget,et al.  Clinician's guide to human papillomavirus immunology: knowns and unknowns. , 2009, The Lancet. Infectious diseases.

[37]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[38]  I. Frazer.  Interaction of human papillomaviruses with the host immune system: a well evolved relationship. , 2009, Virology.

[39]  M. Einstein,et al.  Genetic Variants in TAP Are Associated with High-Grade Cervical Neoplasia , 2009, Clinical Cancer Research.

[40]  D. Pardoll,et al.  A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 , 2009, Clinical Cancer Research.

[41]  J. M. van der Hulst,et al.  Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response , 2008, Clinical Cancer Research.

[42]  Joakim Dillner,et al.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.

[43]  S. Franceschi,et al.  Human Papillomavirus Infection in Ulaanbaatar, Mongolia: A Population-Based Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[44]  H. Kitchener,et al.  HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia , 2008, BJOG : an international journal of obstetrics and gynaecology.

[45]  W. Westra,et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.

[46]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[47]  V. Beral,et al.  Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies , 2007, The Lancet.

[48]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[49]  Mimi Y. Kim,et al.  Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. , 2007, Gynecologic oncology.

[50]  R. Roden,et al.  Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2 , 2007, Journal of Virology.

[51]  J. M. van der Hulst,et al.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens , 2007, Proceedings of the National Academy of Sciences.

[52]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[53]  N. Muñoz,et al.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. , 2007, The Lancet. Infectious diseases.

[54]  R. Burk,et al.  Papillomavirus vaccines in perspective , 2007, The Lancet.

[55]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[56]  T. Iftner,et al.  TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 161 , 2007, The Journal of Immunology.

[57]  Elizabeth R Unger,et al.  Prevalence of HPV infection among females in the United States. , 2007, JAMA.

[58]  S. Franceschi,et al.  Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide , 2006, International journal of cancer.

[59]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[60]  J. Peto,et al.  HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial , 2006, British Journal of Cancer.

[61]  V. Beral,et al.  Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies , 2006, International journal of cancer.

[62]  S. H. van der Burg,et al.  Detection of human papillomavirus type 18 E6 and E7‐specific CD4+ T‐helper 1 immunity in relation to health versus disease , 2006, International journal of cancer.

[63]  M. Einstein,et al.  Vaccine strategies for human papillomavirus-associated cancers , 2005, Current opinion in oncology.

[64]  D. Lowy,et al.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. , 2005, Virology.

[65]  P. Delvenne,et al.  E‐cadherin‐dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus‐associated (pre)neoplastic lesions , 2005, The Journal of pathology.

[66]  R. DeSalle,et al.  The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.

[67]  S. Wacholder,et al.  A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[68]  J. Doorbar.  The papillomavirus life cycle. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[69]  A. Muñoz,et al.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.

[70]  A. Moscicki,et al.  Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. , 2004, The Journal of infectious diseases.

[71]  J. Peto,et al.  Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort , 2004, British Journal of Cancer.

[72]  M. Sherman,et al.  Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica , 2004, British Journal of Cancer.

[73]  J. M. van der Hulst,et al.  Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.

[74]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[75]  J. Palefsky,et al.  Chapter 6: Immunosuppression and co-infection with HIV. , 2003, Journal of the National Cancer Institute. Monographs.

[76]  S. Caldeira,et al.  The role of TP53 in Cervical carcinogenesis , 2003, Human mutation.

[77]  J. M. van der Hulst,et al.  Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. , 2003, Cancer research.

[78]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[79]  J. M. van der Hulst,et al.  Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. , 2002, Cancer research.

[80]  Karl Münger,et al.  Biological activities and molecular targets of the human papillomavirus E7 oncoprotein , 2001, Oncogene.

[81]  P. Porter,et al.  Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. , 2001, Cancer research.

[82]  N. Kiviat,et al.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.

[83]  Jong-Sup Park,et al.  Inactivation of Interferon Regulatory Factor-1 Tumor Suppressor Protein by HPV E7 Oncoprotein , 2000, The Journal of Biological Chemistry.

[84]  A. Singer,et al.  The antigen‐presenting environment in normal and human papillomavirus (HPV)‐related premalignant cervical epithelium , 1999, Clinical and experimental immunology.

[85]  University of ZimbabweJHPIEGO Cervical Cancer Project.  Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting , 1999, The Lancet.

[86]  M. Vidal,et al.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. , 1998, Genes & development.

[87]  B. Moss,et al.  Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. , 1997, The Journal of infectious diseases.

[88]  D. Wazer,et al.  E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. , 1996, Cancer research.

[89]  M. Stanley,et al.  Immunological events in regressing genital warts. , 1994, American journal of clinical pathology.

[90]  Jack Cuzick,et al.  The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC‐US or LSIL cervical cytology: A meta‐analysis of the diagnostic accuracy , 2013, International journal of cancer.

[91]  C. Wheeler,et al.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[92]  Jacques Ferlay,et al.  The global burden of cancers attributable to infections in the year 2008: a review and synthetic analysis Web appendix section , 2012 .

[93]  M. Desai,et al.  HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology : results from the Sentinel Sites study , 2011 .

[94]  J. Cuzick,et al.  Effi cacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia : a randomised controlled trial , 2010 .

[95]  J. Dungan.  Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study , 2010 .

[96]  S. H. van der Burg,et al.  A prospective study on the natural course of low‐grade squamous intraepithelial lesions and the presence of HPV16 E2‐, E6‐ and E7‐specific T‐cell responses , 2010, International journal of cancer.

[97]  Susun Bellew,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2010 .

[98]  B. Thiers.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2009 .

[99]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[100]  M. Einstein,et al.  Combined human papillomavirus DNA and human papillomavirus‐like particle serologic assay to identify women at risk for high‐grade cervical intraepithelial neoplasia , 2007, International journal of cancer.

[101]  C. Woodman,et al.  The natural history of cervical HPV infection: unresolved issues , 2007, Nature Reviews Cancer.

[102]  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. , 2003, American journal of obstetrics and gynecology.

[103]  J. Palefsky,et al.  Immunosuppression and co-infection with HIV , 2003 .